PSMC3
ENSG00000165916
Target class
Enzyme
Chromosome
11
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- PSMC3
- Gene name
- Proteasome 26S subunit, ATPase 3
- Gene symbol
- PSMC3
- Protein name
- 26S proteasome regulatory subunit 6A (26S proteasome AAA-ATPase subunit RPT5) (Proteasome 26S subunit ATPase 3) (Proteasome subunit P50) (Tat-binding protein 1) (TBP-1)
- TBP1
- TBP-1
- RPT5
- Gene biotype
- Protein coding
- Gene family
- AAA ATPases|Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 199.9
- Tissue specificity (Gini)
- 0.17
- Tissue specificity (tau)
- 0.397
- KEGG gene identifiers
- hsa:5702
- Protein interaction confidence
- 0.896286
- Protein interaction partners
- 84
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 47426488
- Start position
- 47418765
- Chromosome
- 11
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Colocalizes with TRIM5 in the cytoplasmic bodies. .
- Cytosol
- Nuclear bodies
- Nucleoplasm
- Tissue specificity (tau)
- 0.397188
- Expression inequality (Gini)
- 0.17027
Expression in transcripts per million
- Artery - Tibial
- 199.9
- Cells - Cultured fibroblasts
- 190.91
- Muscle - Skeletal
- 186.32
- Esophagus - Muscularis
- 175.06
- Esophagus - Gastroesophageal Junction
- 171.77
Expression in transcripts per million
- Artery - Tibial199.9
- Cells - Cultured fibroblasts190.91
- Muscle - Skeletal186.32
- Esophagus - Muscularis175.06
- Esophagus - Gastroesophageal Junction171.77
- Artery - Aorta169.78
- Colon - Sigmoid169.48
- Nerve - Tibial167.7
- Artery - Coronary163.99
- Uterus161.06
- Cells - EBV-transformed lymphocytes155.6
- Testis153.47
- Skin - Sun Exposed (Lower leg)151
- Cervix - Ectocervix149.67
- Cervix - Endocervix147.96
- Brain - Cerebellar Hemisphere143.1
- Brain - Frontal Cortex (BA9)142.01
- Fallopian Tube140.59
- Skin - Not Sun Exposed (Suprapubic)134.95
- Lung134.88
- Thyroid133.71
- Adipose - Subcutaneous132.67
- Brain - Caudate (basal ganglia)127.09
- Brain - Cerebellum126.36
- Bladder126.17
And 29 more, listed on the interactive page.
- GO:0043921
- GO:0045944
- GO:1901800
- GO:0000502
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005829
- GO:0016020
- GO:0034774
- GO:1904813
- GO:0005515
- GO:0036402
- GO:0042802
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor